Coya Therapeutics (NASDAQ:COYA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15, Zacks reports.
Coya Therapeutics Price Performance
Shares of NASDAQ:COYA traded down $0.01 during trading on Friday, reaching $7.21. 48,778 shares of the company's stock traded hands, compared to its average volume of 152,437. Coya Therapeutics has a fifty-two week low of $4.40 and a fifty-two week high of $10.69. The company has a 50-day simple moving average of $7.02 and a 200-day simple moving average of $7.05.
Wall Street Analyst Weigh In
COYA has been the subject of several recent research reports. HC Wainwright assumed coverage on shares of Coya Therapeutics in a report on Monday, September 16th. They set a "buy" rating and a $18.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday.
Get Our Latest Analysis on COYA
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Read More
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
